NASDAQ
10.27USD
-0.44 (-4.11%)
We have scored 29 news catalysts on Oculis Holding AG (OCS) over the past 12 months. The biggest single-day move next to one of them came Jun 3, 2026, when OCS closed +6.9%: “Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)”. Coverage across the window leans negative (average ticker sentiment −0.24). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
589.4M
P/E
—
EPS
—
Beta
0.23
52W range
9.65-34.475
Day range
10.25–10.73
Open
10.64
Prev close
10.71
Volume
20.4K
Avg volume
561.6K
Dividend
0.00
IPO
2021-05-18
Analysts publish price targets on OCS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
5 analyst price targets from $26 to $75
as of 2026-09-14
The market is 72% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Oculis Holding AG — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for OCS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
The price sits 72% below the median analyst target and at the very bottom of the published spread, meaning the market has largely written off the company's former lead program and gives almost no credit to its remaining pipeline.
What the disagreement turns on
Does Privosegtor's PIONEER-1 trial actually succeed and capture a portion of the estimated $7 billion U.S. market opportunity, and none of the data tools wired here can settle that clinical question.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
